28 February 2022
In this episode of Inside IAVI, Finora Franck, senior specialist, laboratory operations, sat down with some of our longest-serving laboratory colleagues to give a glimpse inside our global labs, and to reflect on some of their most formative moments with IAVI.
Jayanta Bhattacharya, director, HIV Vaccine Translational Research Laboratory, Translational Health Science and Technology Institute, India
Paramesh Chetty, associate director, Clinical Laboratory Programme, Pretoria, Gauteng, South Africa
Elise Landais, principal scientist, antibody discovery and development, Neutralizing Antibody Center, California, United States
Aaron Wilson, research scientist, candidate evaluation, Vaccine Design and Development Laboratory, New York, United States
The work in the laboratories discussed in this podcast is made possible by the support of the American People through the United States Agency for International Development (USAID) and the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR). The content of this podcast is the sole responsibility of IAVI and does not necessarily reflect the views of USAID, PEPFAR, or the United States Government.
More about Clinical Research Centers (CRCs): Over a span of more than 20 years, IAVI, with funding from USAID, built a network of Partner Clinical Research Centers (CRCs) in East and Southern Africa, which were initially focused on HIV vaccine trials with the recognition that a vaccine to prevent HIV must reflect the needs of the communities in countries most affected by the epidemic. To achieve this goal, IAVI built partnerships with in-country research institutions and communities to prepare and conduct vaccine trials in developing countries, where the need for a vaccine is greatest.
More about the IAVI Vaccine Design and Development Laboratory (DDL): In 2008, IAVI established the DDL to further research on novel replicating viral vector technology for delivering candidate HIV vaccines. Since its founding, the DDL has become one of the world’s leading vaccine research and development labs, evolving their design of viral vectors based on the vesicular stomatitis virus to develop HIV vaccine candidates.
More about the HIV Vaccine Translational Research (HVTR) Laboratory: The HVTR Laboratory at the Translational Health Science and Technology Institute (THSTI) was established as a joint initiative between the Department of Biotechnology, THSTI, and IAVI in 2012. The HVTR Laboratory studies the genetic and virological properties of circulating HIV strains in India, and complements the efforts of IAVI’s Neutralizing Antibody Center (NAC) to accelerate the development of broadly neutralizing antibodies (bnAbs) that would be affordable and applicable to low- and middle-income countries.
More about IAVI Neutralizing Antibody Center (NAC): IAVI’s NAC was established in 2002, and today is a leading source of innovation in the study of bnAbs and the design of immunogens to elicit these antibodies through vaccination. The NAC brings together leading investigators — including structural and computational biologists, immunologists, protein chemists, and glycobiologists — from institutions worldwide.
Inside IAVI: Special Edition – In conversation with Seth Berkley & Mark Feinberg
16 December 2021
In conversation with Seth Berkley & Mark Feinberg: 25 years of innovation, partnerships, and access
To commemorate IAVI turning 25, we bring you a special edition of Inside IAVI, where we are joined by Mark Feinberg, IAVI president and CEO, and Seth Berkley, IAVI’s founding CEO who is now leading Gavi, The Vaccine Alliance, as they reflect on IAVI’s accomplishments and the current global health landscape.
In this episode, Kristen Abboud, managing editor of IAVI Report, sat down with Mark and Seth to reminisce about the last 25 years of IAVI, reflect on lessons learned as leaders in global health, and discuss what the future holds for IAVI and the global vaccine research and development field at large.
More about Gavi, The Vaccine Alliance: Gavi is a public–private global health partnership with the goal of increasing access to immunization in poor countries. This organization helps vaccinate almost half the world’s children against deadly and debilitating infectious diseases. Gavi is also co-leading COVAX, the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator. This involves coordinating the COVAX Facility, a global risk-sharing mechanism for pooled procurement and equitable distribution of COVID-19 vaccines.
More about IAVI Report: IAVI Report is a scientific publication that provides comprehensive and editorially independent coverage of R&D on vaccines and preventive technologies to address HIV and other global health priorities. The publication features the voices and opinions of those leading these efforts and provides an unparalleled analysis of the latest scientific and policy research.
Inside IAVI: Episode 1 – Sheroes in Global Health
14 September 2021
In this first episode of Inside IAVI, our COO Ana Céspedes is joined by four female colleagues and leaders at IAVI who have spent their careers advancing global health solutions. With tenures ranging from eight to 20 years, the panelists come together to discuss why diversity in global health leadership is important and some of their most formative moments at IAVI.
Smriti Bhagi, associate director, Country and Regional Programs in India
Kundai Chinyenze, M.D., executive medical director, Clinical Development
Pat Fast, M.D., senior technical advisor, R&D Executive Office
Jennifer Lehrman, senior director, Clinical Alliances in Clinical Development